BL2 (Burkitt lymphoma), RI-1 and U2932 (NGCB-DLBCL cell lines),and SU-DHL-4 (GCB-DLBCL cell lines), characterized by the surfaceexpression of CXCR4, were treated with both compounds, thus provingthe ability of WK1 to inhibit BL2 and SU-DHL-4 cell growth at IC50 values of 15.4 and 26.76 μM, respectively, as wellas that of AMD070 at IC50 values of 31.18 and 26.76 μM.Compared to plerixafor, WK1 showed more pronounced proapoptotic effectscoupled with higher level of cleaved caspase-3 and induction of BCL2proapoptotic genes. The gene discussed is CXCR4; the disease is diffuse large B-cell lymphoma.